MAPT and Alzheimer disease: Consequently, we aimed to determine the effects of Lf intervention on cognitive function by utilizing both young (10 weeks) and middle-aged (24 weeks) APP/PS1 mice as models; we also investigated alterations of the key makers involved in AD pathology (i.e. Aβ, tau phosphorylation, neuro-inflammation and synaptic plasticity related proteins), as well as the cecal microbiome post Lf intervention.